Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1070 results about "Leucine" patented technology

Leucine (symbol Leu or L) is an essential amino acid that is used in the biosynthesis of proteins. Leucine is an α-amino acid, meaning it contains an α-amino group (which is in the protonated −NH₃⁺ form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO⁻ form under biological conditions), and a side chain isobutyl group, making it a non-polar aliphatic amino acid. It is essential in humans, meaning the body cannot synthesize it: it must be obtained from the diet. Human dietary sources are foods that contain protein, such as meats, dairy products, soy products, and beans and other legumes. It is encoded by the codons UUA, UUG, CUU, CUC, CUA, and CUG.

Engineered transgene integration platform (ETIP) for gene targeting and trait stacking

An Engineered Transgene Integration Platform (ETIP) is described that can be inserted randomly or at targeted locations in plant genomes to facilitate rapid selection and detection of a GOI that is perfectly targeted (both the 5′ and 3′ ends) at the ETIP genomic location. One element in the subject disclosure is the introduction of specific double stranded breaks within the ETIP. In some embodiments, an ETIP is described using zinc finger nuclease binding sites, but may utilize other targeting technologies such as meganucleases, CRISPRs, TALs, or leucine zippers. Also described are compositions of, and methods for producing, transgenic plants wherein the donor or payload DNA expresses one or more products of an exogenous nucleic acid sequence (e.g. protein or RNA) that has been stably-integrated into an ETIP in a plant cell. In embodiments, the ETIP facilitates testing of gene candidates and plant expression vectors from ideation through Development phases.
Owner:CORTEVA AGRISCIENCE LLC

Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes

A complex is provided for the treatment of neurogenic conditions having the formula: where R1 is M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium (II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium (II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium (II):transporter ligand.
Owner:MILLER LANDON C G

Composition for stabilizing corneal tissue during or after orthokeratology lens wear

InactiveUS6946440B1Stay in shapeSenses disorderEye implantsCuticleLeucine-rich repeat proteins
Two types of compositions having an eye-drop delivery system are used during or after an orthokeratology procedure to prevent or retard relaxation of corneal tissue back to the original anterior curvature of the cornea. Each composition functions independently from the others and is a different approach of preparing a stabilizing agent. The first composition is directed to a biologically compatible composition comprising fibril associated collagens with interrupted triple helices (FACITs) and / or small leucine-rich repeat proteoglycans (SLRPs). The fibril associated collagen family includes various types of collagens, such as type VI, type XX, type XII, and type XIV. The small leucine-rich repeat proteoglycans family includes decorin, keratocan, biglycan, epiphycan, lumican, mimecan, and fibromodulin. The second composition includes the enzyme found as a normal component of tissues, plasma, or epidermis, such as transglutaminase.
Owner:EUCLID SYST CORP +2

Compositions and methods for modulating metabolic pathways

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
Owner:NUSIRT SCI

Composition for an in vitro fertilization medium

PCT No. PCT / JP96 / 02503 Sec. 371 Date Mar. 2, 1998 Sec. 102(e) Date Mar. 2, 1998 PCT Filed Sep. 4, 1996 PCT Pub. No. WO97 / 08946 PCT Pub. Date Mar. 13, 1997The present invention aims to provide a medium composition for in vitro fertilization, in particular, a composition usable in the culture of ova or early embryos which are fertilized eggs, the preparation or culture of sperm, and the pre-treatment of ova or sperm. The composition comprises, as its essential components, L-phenylalanine, L-tryptophan, L-lysine, L-threonine, L-valine, L-methionine, L-isoleucine, L-leucine, L-proline, glycine, L-alanine, L-tyrosine, L-histidine, L-arginine, L-taurine, L-aspartic acid, L-serine, L-asparagine, L-glutamic acid, L-glutamine and L-cystine, provided that at least a part of the L-cystine may be replaced by L-cysteine.
Owner:FUSO PHARMA INDS

Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders

A compound is provided that has the formula NH2CH2CH2CH2C(O)N—R   (I) where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.
Owner:MILLER LANDON C G

Surfactant peptide nanostructures, and uses thereof

This work describes a new class of short polypeptides that can self-assemble to form regular nanotubes with an average diameters of about 50 nm. These peptides (7 to 8 amino acids) have a structure very similar to those observed in surfactant molecules with a defined hydrophilic head group constituting of charged amino acids and a lipophilic tail made out of hydrophobic amino acids such as alanine, valine or leucine. Cryo-TEM micrographs show numerous three-fold junctions connecting the self-assembling nanostructures and thus leading to the formation of a rather dense network of entangled nanotubes. Additionally, the observation of clear openings at the end of the supramolecular structures confirms the presence of tubular organization.
Owner:MASSACHUSETTS INST OF TECH

Compositions and methods for glycogen synthesis

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and / or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and / or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.
Owner:TSI INC

Methods for enhancing the transport of glucose into muscle

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and / or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.
Owner:TSI INC

Medicinal compositions & therapeutic methods

The compositions of this invention comprise a mixture of (1) phenylalanine and a dietary food supplement, (2) leucine and a dietary food supplement, and (3) hydrocinnamic acid and a dietary food supplement. The compositions are used for medicinal purposes to alleviate a variety of maladies.
Owner:WELLER HEALTH

Mutated Immunoglobulin-Binding Polypeptides

ActiveUS20160159857A1Highly selective bindingImproved alkaline stabilitySolid sorbent liquid separationDepsipeptidesTryptophanMutant
The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.
Owner:CYTIVA BIOPROCESS R&D AB

Compositions and methods for modulating metabolic pathways

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
Owner:NUSIRT SCI

Transaminase mutant and application thereof

The invention discloses a transaminase mutant and application thereof. The amino acid sequence of the transaminase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO:1, and the mutation at least comprises one of the following mutation sites: the 19th site, the 41st site, the 43rd site, the 72nd site, the 76th site, the 92nd site, the 107th site, the 125th site, the 132nd site, the 226th site, the 292nd site, the 295th site, the 308th site and the 332nd site; the 19th mutation is serine, the 41st mutation is serine, the 43rd mutation is asparagine, and the 72nd glycinemutation is leucine; or the amino acid sequence of the transaminase mutant has mutation sites in a mutated amino acid sequence, and has 80% or more homology with the mutated amino acid sequence. The transaminase mutant disclosed by the invention greatly reduces the cost in industrial production of chiral amine.
Owner:天津凯诺医药科技发展有限公司

Meaty paste essence and preparation method thereof

The invention discloses meaty paste essence and a preparation method thereof. The meaty paste essence comprises the following components in part by weight: 10 to 30 parts of L-cysteine, 15 to 20 parts of vitamin B, 20 to 40 parts of glucose, 10 to 20 parts of L-leucine, 5 to 10 parts of DL-methionine, 2 to 8 parts of alanine, 50 to 150 parts of yeast fine paste, 200 to 300 parts of bean pulp zymolyte, 2 to 5 parts of disodium inosinate and disodium guanylate (I+G), 30 to 60 parts of soy sauce, 50 to 80 parts of animal fat, 50 to 80 parts of salt, 50 to 100 parts of white granulated sugar, 1 to 3 parts of xanthan gum, 50 to 100 parts of sodium glutamate, 30 to 60 parts of corn starch and 10 to 30 parts of meaty flavoring base. The meaty paste essence prepared by combining the Maillard reaction technology and the bean pulp proteolysis technology has good mouthfeel, high environment-friendly indexes, stable quality, low cost and high safety performance.
Owner:TIANNING FLAVOR JIANGSU

Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders

A compound is provided that has the formula NH2CH2CH2CHR1C(O)N—R  (I) where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.
Owner:MILLER LANDON C G

Rice blast resistance gene Pi7 and application thereof

The invention discloses a rice blast resistance gene Pi7 and application thereof, and provides a nucleotide sequence of the rice blast resistance gene Pi7 and an amino acid polypeptide sequence coded thereby. The nucleotide sequence comprises two genes which belong to members of a coiled-coil nucleotide binding site leucine-rich repeat (CC-NBS-LRR) resistance gene family and are constitutive expression genes. The invention also provides application of the gene to the aspect of transforming rice or breeding disease-resistant varieties of other plants and application of a molecular marker produced according to the gene sequence to breeding.
Owner:SOUTH CHINA AGRI UNIV

Charged nutritive proteins and methods

Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g / L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g / L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g / L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
Owner:AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS) LLC

Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption

The invention relates to a composition comprising carbohydrate and peptide material as well as an amount of at least one additional free amino acid selected from the group consisting of leucine and phenylalanine. This composition will enhance the blood insulin response after oral intake by humans and is intended for an enhanced recovery air physical exercise or to delay exhaustion during physical exercise.
Owner:QUEST INTERNATIONAL

Synthetic method of kyprolis

The invention relates to the technical field of drug synthesis, and particularly relates to a synthetic method of kyprolis. The synthetic method comprises the following steps: carrying out condensation reaction on morpholine-4-base acetic acid, L-homophenylalanine ester and salt, and then carrying out decarboxylation protection to generate a compound V; carrying out the condensation reaction on the decarboxylation, the salt and N-Boc-L-leucine, and then carrying out deamination protection to generate a compound VI; carrying out the condensation reaction on the compound V and the compound VI, and then carrying out decarboxylation protection to generate a compound VII; carrying out the condensation reaction on the compound VII and a compound VIII to obtain the kyprolis. The method disclosed by the invention can be used for enhancing the reaction yield by adopting a converging synthetic method; the used reagent is easy, convenient, easy to obtain and less in pollution. The process disclosed by the invention only relates to the condensation and deprotection between amino acids and is simple and controllable in reaction and suitable for industrial production.
Owner:重庆兴泰濠制药有限公司

Plants having improved growth characteristics and a method for making the same

The present invention relates generally to the field of molecular biology and concerns a method for improving plant growth characteristics relative to corresponding wild type plants. More specifically, the present invention concerns a method for improving plant growth characteristics comprising modulating expression in a plant of a nucleic acid encoding a class I homeodomain leucine zipper (HDZip) hox5 polypeptide or a homologue thereof; or comprising modulating expression in a plant of a nucleic acid encoding a nitrate transporter protein (NRT) or a homologue thereof; or comprising modulating expression in a plant of a nucleic acid encoding a polypeptide denoted Yield Enhancing Protein 16 (YEP16); or comprising modulating expression in a plant of a Group I glycogen synthase kinase (Group I shaggy-like kinase) or a homologue thereof. The present invention also concerns plants having modulated expression of a nucleic acid encoding a class I HDZip hox5 polypeptide or a homologue thereof; or having modulated expression of a nucleic acid encoding a NRT protein or a homologue thereof; or having modulated expression of a nucleic acid encoding a polypeptide denoted YEP16; or having modulated expression of a Group I shaggy-like kinase or a homologue thereof, which plants have improved growth characteristics relative to corresponding wild type plants. The invention also provides constructs useful in the methods of the invention.
Owner:CROPDESIGN NV

Method for producing an L-amino acid using a bacterium with an optimized level of gene expression

A method is provided for obtaining an L-amino acid or nucleic acid-producing bacterium belonging to the genus Escherichia with an optimized level of expression of the gene which influences the distribution of carbon flow, such as the sucAB genes, comprising introducing into the chromosome of the bacterium a set of in vitro constructed DNA fragments which contain regulatory elements for gene expression instead of the native elements of the regulatory region of the gene, and selecting the colonies with increased L-amino acid productivity. Also, a method is provided for producing an L-amino acid, such as L-glutamic acid, L-proline, L-arginine, L-glutamine, L-leucine, using the bacterium with an optimized level of expression of the sucAB gene.
Owner:AJINOMOTO CO INC

Chinese herbal medicine compound amino acid feed additive and preparation method thereof

The invention provides a Chinese herbal medicine compound amino acid feed additive and a preparation method thereof. The Chinese herbal medicine compound amino acid feed additive is mainly prepared from the following raw materials in parts by weight: 20 to 35 parts of water soluble vitamin, 20 parts of compound amino acid, and 40 to 45 parts of traditional Chinese medicine powder, wherein the traditional Chinese medicine is prepared from astragalus polysaccharide, lumbricus, bombyx batryticatus, ginseng, decumbent bugle herb and liquorice; the water soluble vitamin comprises vitamin B1, vitamin B2, vitamin B6, vitamin B12, 96% of envelope VC, and 35% of VC ester; the compound amino acid is composed of lysine, methionine, cystine, glutamic acid, arginine, tryptophan, phenylalanine, threonine, leucine, glycine and serine. The Chinese herbal medicine compound amino acid feed additive is mixed with normal feed for feeding animals, and can be used for speeding up the animal metabolism, whetting the appetite, prompting the growth, preventing the hypoimmunity as well as the poor growth due to deficiency of vitamin, amino acid and protein, and effectively reducing the risk in feeding.
Owner:防城港市天办海洋科技有限公司

Self-assembly antibacterial peptide

The invention provides self-assembly antibacterial peptide, and belongs to the field of self-assembly polypeptide.The sequence of the antibacterial peptide is Nap-Phe-Phe-Lys-Pro-Leu-Gly-Leu-Ala-Arg-Lys (Nap represents a naphthyl group, Phe represents phenylalanine, Lys represents lysine, Pro represents proline, Leu represents leucine, Gly represents glycine, Ala represents alanine and Arg represents arginine), and the antibacterial peptide is cationic amphiphilic oligopeptide.The antibacterial peptide has good self-assembly capacity, and the self-assembly behaviors present enzyme responsiveness.The antibacterial peptide has no toxicity to Gram negative bacteria, human cells and animal cells within a specific concentration range (50-150 micrometers), has powerful selective killing capacity only for Gram positive bacteria and has good antibacterial activity and selectivity in other words.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)

Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis

The present invention relates to the use of a low-caloric high-protein nutritional composition for use in the prevention or treatment of a disease or condition in a mammal, which involves muscle decline, as well as to specific low-caloric high-protein nutritional compositions for stimulating muscle protein synthesis in a mammal. In particular, the invention relates to the use of a nutritional composition comprising per 100 kcal: (i) at least about 12 g of proteinaceous matter which comprises at least about 80 weight % of whey protein, relative to the total proteinaceous matter, and which comprises at least about 11 weight % of leucine, relative to the total proteinaceous matter, of which at least about 20 weight % is in a free form, relative to the total leucine, (ii) a source of fat and a source of digestible carbohydrates, for the prevention or treatment of a disease or condition which involves muscle decline in a mammal, especially an elderly mammal, wherein the nutritional composition is administered as 1 to 2 servings daily, each serving comprising between 80 and 200 kcal.
Owner:NV NUTRICIA

Cigarette aroma enhancement humectant 1-L-leucine-1-deoxidation-D-fructose and preparation method thereof

The invention discloses cigarette aroma enhancement humectant 1-L-leucine-1-deoxidation-D-fructose. The structural formula of the cigarette aroma enhancement humectant 1-L-leucine-1-deoxidation-D-fructose is as follows. The invention further discloses a preparation method of the compound. D-mannose is taken as a raw material, and the cigarette aroma enhancement humectant 1-L-leucine-1-deoxidation-D-fructose is successfully synthesized through simple reaction processing. Physical humectant performance tests and inherent sensory quality evaluations show that the humectant has a good physical humectant effect on cigarettes, and can reduce irritation and blended gases of the cigarettes and improve the smoke mellow sense and comfort of the cigarettes.
Owner:CHINA TOBACCO HENAN IND +1

Nitrogen/sulfur-doped graphene quantum dots and preparation method thereof, and application of quantum dots in preparing lysine fluorescence detection reagents

The invention relates to a nitrogen / sulfur-doped graphene quantum dots and a preparation method thereof, and application of quantum dots in preparing lysine fluorescence detection reagents. By adopting the product of the thiocarbamide / citric acid hydrothermal reaction, the nitrogen / sulfur-doped graphene nano quantum dots have the multiple electron characteristic, have the advantages of favorable water dispersibility, excellent biocompatibility, rich oxygen-containing functional groups (-COOH, -OH and -O-), high luminescence and high quantum efficiency. The quantum dots have high selectivity and sensitivity to lysine. The synthesis method is simple, and has the advantages of mild conditions and accessible product. When being used for testing lysine, the quantum dots are free of influence of other conventional coexisting amino acids and saccharide biomolecules (such as alanine, proline, glycinate, methionine, arginine, leucine, glucose, glucosamine, galactose, sucrose and the like), and have high selectivity.
Owner:WENZHOU MEDICAL UNIV

Non-interpenetrating chiral MOF stationary phase, its preparation method and application in enantiomer separation in HPLC

The invention relates to a non-interpenetrating chiral MOF (metal organic framework) stationary phase, its preparation method and application in enantiomer separation in HPLC (high-performance liquid chromatography). The stationary phase is a non-interpenetrating chiral three-dimensional porous framework complex with a structural formula as {[ZnL].H2O}n. An asymmetric structural unit {[ZnL].H2O} of the complex is composed of a Zn<2+>, an L ligand and a guest water molecule. The L ligand is -NH- containing chiral pyridine carboxylic acid, its chemical composition is [(N-(4-pyridylmethyl)-L-leucine.HBr)], and its molecular formula is C12H19BrN2O2. Chiral amino acid and 4-pyridylaldehyde are selected as raw materials to synthesize the-NH- containing pyridine carboxylic acid chiral ligand by a one-step process. The ligand and zinc acetate are adopted as raw materials to undergo room temperature diffusion so as to obtain the MOF stationary phase. The material provided in the invention has uniform chiral helical channel, uniform aperture and orifice, and can be used for separation of chiral drugs and other enantiomers. The separation is selectively dependent on the size of a separated enantiomer molecular size, but is not dependent on the functional group of the separated enantiomer. Thus, the non-interpenetrating chiral MOF stationary phase has the characteristics of traditional zeolite molecular sieve separation.
Owner:SHANDONG NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products